Rebound bei Achilles Therapeutics

Aktuell 18 Prozent Plus




www.nasdaq.com/market-activity/stocks/achl/real-time
www.marketbeat.com/stocks/NASDAQ/ACHL/price-target/

achillestx.com/

Zahlen für Q4/22

• keine Umsätze
  
• Verlust 24 Mio. $
  
• Cash 173 Mio. $
  
• MK 36 Mio. $
  

- supports operations into mid-2025

ir.achillestx.com/news-releases/...-quarter-and-year-end-2022

Zahlen für Q1/23

• keine Umsätze
  
• Verlust 17,5 Mio. $
  
• Cash 159 Mio. $
  
• MK 40 Mio. $
  

ir.achillestx.com/news-releases/...rst-quarter-2023-financial

Weiterhin ein Cash-Play Kandidat. Bei 22 Mio. $ Schulden und geschätzten 18 Mio. $ Verlust in Q2/23 ergibt sich ein Cashwert von rund 120 Mio. $ vs. 40 Mio. $ MK, demzufolge läge der theoretische Cashwert bei ca. 3$.

Zahlen für Q2/23

• kein Umsatz
  
• Verlust 17 Mio. $
  
• Cash 144 Mio. $
  
• MK 37 Mio. $
  

-klinische und translationale wissenschaftliche Daten aus den laufenden Phase-I/IIa-Studien zu NSCLC und Melanomen werden im vierten Quartal 2023 erwartet

-supports operations through 2025

ir.achillestx.com/news-releases/...ond-quarter-2023-financial

Zahlen für Q3/23

• keine Umsätze
  
• Verlust 17 Mio. $
  
• Cash 140 Mio. $
  
• MK 33 Mio. $
  

– Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024

– Strong cash position of $140 million supports operations through 2025

ir.achillestx.com/news-releases/...ird-quarter-2023-financial

Achilles Therapeutics Announces Strategic Update
RHEA-AI IMPACT
Rhea-Al SentIment
TAGS
(Moderate)
(Neutral)
RHEA-AISUMMARY
Achilles Therapeutics (NASDAQ: ACHL) has announced a strategic update, discontinuing its TIL-based cNeT therapy program and closing the Phase l/lla CHIRON and THETIS clinical trials. The company will refocus on exploring partnerships with third parties developing alternative modalities targeting clonal neoantigens for cancer treatment. Achilles has engaged BofA Securities to advise on value-maximizing strategies, Key points:
Cash position of $95.1 million as of June 30, 2024 Implementing workforce reduction and cost-cutting measures Full clinical data from CHIRON and THETIS trials to be presented in an upcoming • forum • Exploring strategic alternatives, including potential acquisition, merger, or asset sale